Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2.98	2.13	3	7.06	16.04
Short-Term Investments	9.78	11.77	31.93	43.94	59.56
Cash & Cash Equivalents	12.76	13.9	34.93	51	75.6
Cash Growth	-8.20%	-60.21%	-31.51%	-32.54%	-16.17%
Receivables	0.48	0.83	1.13	0.81	0.83
Total Current Assets	13.24	14.72	36.05	51.81	76.43
Property, Plant & Equipment	0.13	0.34	0.55	0.57	0.71
Long-Term Investments	3.27	1.5	0	0	0
Total Long-Term Assets	3.39	1.84	0.55	0.57	0.71
Total Assets	16.63	16.56	36.61	52.38	77.14
Accounts Payable	2.75	3.09	5.88	8.01	6.93
Total Current Liabilities	2.75	3.09	5.88	8.01	6.93
Long-Term Debt	0	0.04	0.23	0.22	0.35
Total Long-Term Liabilities	0	0.04	0.23	0.22	0.35
Total Liabilities	2.75	3.14	6.11	8.23	7.29
Total Debt	0	0.04	0.23	0.22	0.35
Debt Growth	-	-80.79%	6.02%	-38.64%	-
Retained Earnings	-192.95	-186.04	-168.17	-135.71	-106.94
Comprehensive Income	-0.45	-0.75	-0.17	0.27	0.04
Shareholders' Equity	13.88	13.42	30.5	44.15	69.85
Net Cash / Debt	12.76	13.86	34.7	50.78	75.25
Net Cash / Debt Growth	-7.91%	-60.07%	-31.67%	-32.52%	-16.56%
Net Cash Per Share	4.61	8.27	21.16	35.79	53.46
Working Capital	10.49	11.63	30.18	43.8	69.5
Book Value Per Share	5.01	8.01	18.60	31.12	49.62

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).